Alliance Global Partners Maintains Buy on NeuroOne Medical Tech, Lowers Price Target to $2.2
Portfolio Pulse from Benzinga Newsdesk
Alliance Global Partners analyst Ben Haynor has maintained a 'Buy' rating on NeuroOne Medical Tech (NASDAQ:NMTC), but lowered the price target from $3.25 to $2.2.
August 15, 2023 | 2:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
NeuroOne Medical Tech's price target has been lowered from $3.25 to $2.2 by Alliance Global Partners, though the 'Buy' rating is maintained.
The lowering of the price target by Alliance Global Partners could potentially lead to a short-term negative impact on NeuroOne Medical Tech's stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100